CytomX Therapeutics Inc (NASDAQ: CTMX) stock closed at $3.74 on 10/20/25 after a major increase of 16.9%. Moreover, above average trading volume at 148% of normal accompanied the advance. The stock has risen 11.3% during the last week and has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
CytomX Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment